 Interferon-gamma
"Interferon-gamma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
| Descriptor ID |
D007371
|
| MeSH Number(s) |
D12.644.276.374.440.893 D12.644.276.374.480.350 D12.644.276.374.480.615.350 D12.644.276.718.550 D12.776.467.374.440.893 D12.776.467.374.480.350 D12.776.467.374.480.615.350 D12.776.467.718.550 D23.529.374.440.893 D23.529.374.480.350 D23.529.374.480.615.350 D23.529.718.550
|
| Concept/Terms |
Interferon-gamma- Interferon-gamma
- Type II Interferon
- Interferon, Type II
- Interferon, gamma
- Interferon, Immune
- Immune Interferon
- gamma-Interferon
- Interferon Type II
|
Below are MeSH descriptors whose meaning is more general than "Interferon-gamma".
Below are MeSH descriptors whose meaning is more specific than "Interferon-gamma".
This graph shows the total number of publications written about "Interferon-gamma" by people in this website by year, and whether "Interferon-gamma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1986 | 1 | 0 | 1 | | 1987 | 3 | 2 | 5 | | 1988 | 5 | 2 | 7 | | 1989 | 4 | 2 | 6 | | 1990 | 3 | 3 | 6 | | 1991 | 2 | 3 | 5 | | 1992 | 3 | 4 | 7 | | 1993 | 2 | 5 | 7 | | 1994 | 3 | 3 | 6 | | 1995 | 6 | 4 | 10 | | 1996 | 2 | 4 | 6 | | 1997 | 2 | 4 | 6 | | 1998 | 6 | 5 | 11 | | 1999 | 2 | 8 | 10 | | 2000 | 3 | 4 | 7 | | 2001 | 7 | 7 | 14 | | 2002 | 3 | 10 | 13 | | 2003 | 4 | 10 | 14 | | 2004 | 6 | 19 | 25 | | 2005 | 4 | 8 | 12 | | 2006 | 3 | 10 | 13 | | 2007 | 5 | 10 | 15 | | 2008 | 8 | 11 | 19 | | 2009 | 1 | 11 | 12 | | 2010 | 1 | 10 | 11 | | 2011 | 8 | 9 | 17 | | 2012 | 2 | 13 | 15 | | 2013 | 1 | 9 | 10 | | 2014 | 2 | 9 | 11 | | 2015 | 2 | 5 | 7 | | 2016 | 1 | 5 | 6 | | 2017 | 1 | 4 | 5 | | 2018 | 1 | 4 | 5 | | 2019 | 1 | 4 | 5 | | 2020 | 2 | 5 | 7 | | 2021 | 1 | 3 | 4 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interferon-gamma" by people in Profiles.
-
Pandey SP, Bender MJ, McPherson AC, Phelps CM, Sanchez LM, Rana M, Hedden L, Sangani KA, Chen L, Shapira JH, Siller M, Goel C, Verdú EF, Jabri B, Chang A, Chandran UR, Mullett SJ, Wendell SG, Singhi AD, Tilstra JS, Pierre JF, Arteel GE, Hinterleitner R, Meisel M. Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis. Cell Host Microbe. 2022 07 13; 30(7):1003-1019.e10.
-
Pusic KM, Kraig RP, Pusic AD. IFN?-stimulated dendritic cell extracellular vesicles can be nasally administered to the brain and enter oligodendrocytes. PLoS One. 2021; 16(8):e0255778.
-
Rao E, Hou Y, Huang X, Wang L, Wang J, Zheng W, Yang H, Yu X, Yang K, Bugno J, Ding X, Vokes E, Fu YX, Weichselbaum RR, Liang HL. All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Sci Immunol. 2021 06 15; 6(60).
-
Li ZY, Morman RE, Hegermiller E, Sun M, Bartom ET, Maienschein-Cline M, Sigvardsson M, Kee BL. The transcriptional repressor ID2 supports natural killer cell maturation by controlling TCF1 amplitude. J Exp Med. 2021 06 07; 218(6).
-
Lejeune T, Meyer C, Abadie V. B Lymphocytes Contribute to Celiac Disease Pathogenesis. Gastroenterology. 2021 06; 160(7):2608-2610.e4.
-
Zheng W, Ranoa DRE, Huang X, Hou Y, Yang K, Poli EC, Beckett MA, Fu YX, Weichselbaum RR. RIG-I-Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy. Cancer Res. 2020 12 15; 80(24):5633-5641.
-
Harris KM, Horn SE, Grant ML, Lang H, Sani G, Jensen-Wachspress MA, Kankate VV, Datar A, Lazarski CA, Bollard CM, Keller MD. T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1. Front Immunol. 2020; 11:575977.
-
Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. Conserved Interferon-? Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020 10 12; 38(4):500-515.e3.
-
Choi JW, Withers SS, Chang H, Spanier JA, De La Trinidad VL, Panesar H, Fife BT, Sciammas R, Sparger EE, Moore PF, Kent MS, Rebhun RB, McSorley SJ. Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. PLoS One. 2020; 15(7):e0235518.
-
Ibrahim S, Harris-Kawano A, Haider I, Mirmira RG, Sims EK, Anderson RM. A novel Cre-enabled tetracycline-inducible transgenic system for tissue-specific cytokine expression in the zebrafish: CETI-PIC3. Dis Model Mech. 2020 06 26; 13(6).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|